Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) – Equities researchers at Zacks Investment Research increased their FY2018 earnings per share (EPS) estimates for shares of Brainstorm Cell Therapeutics in a note issued to investors on Tuesday, October 30th. Zacks Investment Research analyst D. Bautz now forecasts that the biotechnology company will post earnings of ($0.61) per share for the year, up from their previous estimate of ($0.62).
BCLI has been the subject of several other reports. HC Wainwright set a $11.00 price target on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Monday, August 27th. Maxim Group reissued a “buy” rating and issued a $9.00 price target on shares of Brainstorm Cell Therapeutics in a report on Thursday, September 13th.
BCLI opened at $3.38 on Thursday. The company has a market capitalization of $64.61 million, a PE ratio of -13.00 and a beta of 2.01. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.35.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Monday, October 29th. The biotechnology company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.05).
An institutional investor recently raised its position in Brainstorm Cell Therapeutics stock. Renaissance Technologies LLC grew its holdings in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) by 29.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,400 shares of the biotechnology company’s stock after buying an additional 26,299 shares during the quarter. Renaissance Technologies LLC owned about 0.56% of Brainstorm Cell Therapeutics worth $450,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 11.78% of the company’s stock.
Brainstorm Cell Therapeutics Company Profile
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Featured Article: Investing in Dividend Stocks
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.